From Trauma & Addiction
Pharmaceutical-Grade Ibogaine, Manufactured to GMP Standards
Supporting evidence-based research and medically supervised treatment pathways for PTSD, traumatic brain injury, and opioid use disorder. Ibogaine is not FDA-approved. mPath supports research, clinical supply, and regulated treatment in licensed jurisdictions.
Sources: CDC, NIH, VA Suicide Prevention, NIMH
Ibogaine is a naturally occurring compound extracted from the root of the African shrub Tabernanthe iboga. Today, it's gaining global attention for its remarkable potential to treat mental health and addiction challenges at the neurological level.
Adjusts brain neurochemistry to break dependency patterns at their source
Acts on opioid receptors to significantly reduce withdrawal severity in supervised settings
Promotes neuroplastic changes associated with recovery
Produces a powerful antidepressant metabolite with sustained effects
Aids in trauma processing and emotional healing for long-term recovery
Allows behavioral modification therapy to be significantly more effective
Peer-reviewed studies demonstrate ibogaine's remarkable efficacy
Stanford University
Stanford researchers examined effects of a single Ibogaine treatment on 30 US veterans with Traumatic Brain Injuries and PTSD in a rigorous clinical trial.
UC Davis Health
Comprehensive analysis of ten research studies examining ibogaine's efficacy in treating opioid addiction and associated psychological symptoms.
mPath Therapeutics is standardizing and manufacturing pharmaceutical-grade Ibogaine from the Tabernanthe Iboga shrub. With over $5M invested in state-of-the-art GMP manufacturing facilities, we deliver hospital-administered treatment with compassionate rehabilitation and aftercare.
Montego Bay, Jamaica
Medical supervision in controlled clinical environments with resort-quality recovery
From ethically sourced material to comprehensive aftercare
Iboga powder from source country
Compliance with Nagoya Protocols
Certified extraction & manufacturing
Pharmaceutical-grade standards
Comprehensive patient evaluation
In-hospital ibogaine protocols
Rehab & co-therapies
mPath's leadership combines pharmaceutical manufacturing, regulatory oversight, clinical medicine, and capital markets experience in highly regulated industries.
Founder / CEO
Founded 48 North, Canada's 39th Licensed Producer of cannabis, taking it public before acquisition by Hexo/Tilray. Co-founder of Pure Jamaican and Seven 10 Pharmaceuticals. 20+ years leading startup companies.
Chief Ibogaine Officer
Co-author of Manual for Ibogaine Therapy with pioneer Howard Lotsof. 100+ patients treated. Co-founded Global Ibogaine Treatment Alliance and MMJ-Phytotech Ltd, Australia's first public medical cannabis company.
Chief Medical Officer
Psychiatrist. Former CMO for Jamaica's Ministry of Health & Wellness. Chairman and Founding Member of Caribbean Psychedelic Association. Regimental Medical Director, Jamaican Defence Force.
Chief Regulatory Officer
Order of Jamaica recipient (Commander Class). 30-year Pharmacy Council board member. Dean, College of Health Sciences at UTech. Former President, Pharmaceutical Society of Jamaica.
Chief Financial Officer
Former CFO at 48 North, oversaw construction of production facility and Health Canada approval. 30+ years financial experience with private and public companies in regulated industries.
Ibogaine is a naturally occurring psychoactive substance found in the root bark of the African shrub Tabernanthe iboga. It has been traditionally used in spiritual rituals and is now being explored for its potential in treating various addiction and mental health disorders.
Ibogaine works by interacting with multiple neurotransmitter systems in the brain, including opioid receptors. It helps reduce withdrawal symptoms and cravings by resetting the brain's chemical balance, offering a potential pathway to long-term recovery.
Ibogaine is primarily used to treat opioid use disorder. It is also being studied for its benefits in treating other substance use disorders, post-traumatic stress disorder (PTSD), and traumatic brain injuries (TBIs).
Individuals with certain cardiac, hepatic, or psychiatric conditions may be excluded from treatment following screening. mPath treatment is administered in a hospital under physician supervision with full cardiac monitoring.
The legality of Ibogaine varies by country. In some places it is classified as a controlled substance. In other regions, including Jamaica, it is used legally for medical or research purposes under appropriate licensing.
During an Ibogaine session, patients may experience psychoactive effects including visual and auditory experiences. These typically last 18-36 hours. Treatment is conducted in a safe, supportive hospital environment with medical doctors present throughout.
Ibogaine treatment should only be administered under medical supervision in a controlled environment—mPath Ibogaine treatment is administered in a hospital under physician supervision.
Advancing Pharmaceutical-Grade Ibogaine for Evidence-Based Mental Health Treatment
